Darovasertib is an investigational oral small-molecule protein kinase C inhibitor being developed for metastatic uveal melanoma and other cancers. It targets PKC activation driven by mutant GNAQ/GNA11, alterations that are frequent in uveal melanoma. The drug remains in clinical development and is not approved.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07015190 |
Neoadjuvant Darovasertib in Primary Uveal Melanoma |
RECRUITING | PHASE3 |
| NCT05907954 |
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05187884 |
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma |
COMPLETED | PHASE2 |
